-
公开(公告)号：US20140275026A1
公开(公告)日：2014-09-18
申请号：US14206028
申请日：2014-03-12
Applicant: AbbVie Inc.
Inventor： Le Wang , John Pratt , Lisa A. Hasvold , Dachun Liu , Yujia Dai , Steven D. Fidanze , James H. Holms , Robert A. Mantei , Keith F. McDaniel , George S. Sheppard , William J. McClellan
IPC: C07D471/04
CPC classification number: C07D471/04 , C07D519/00
Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, and R5 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
Abstract translation: 本发明提供式（I）化合物，其中R 1，R 2，R 3，R 4和R 5具有说明书中定义的任何值及其药学上可接受的盐，其可用作治疗疾病和病症的试剂 ，包括炎性疾病，癌症和艾滋病。 还提供了包含一种或多种式（I）化合物的药物组合物。
-
12.发明申请公开(公告)号：US20140057890A1
公开(公告)日：2014-02-27
申请号：US14058164
申请日：2013-10-18
Applicant: AbbVie Inc.
Inventor： Milan Bruncko , Hong Ding , George A. Doherty , Steven W. Elmore , Lisa Hasvold , Laura A. Hexamer , Aaron R. Kunzer , Robert A. Mantei , William J. McClellan , Chang H. Park , Cheol-Min Park , Andrew M. Petros , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Gary T. Wang , Le Wang , Xilu Wang , Michael D. Wendt
IPC: A61K31/5377 , A61K31/496 , C07D413/06 , C07D401/06 , A61K45/06 , A61K31/407 , C07D403/06 , A61K31/501 , C07D241/04 , A61K31/495 , C07D405/06 , C07D487/04
CPC classification number: C07D401/12 , A61K31/407 , A61K31/495 , A61K31/496 , A61K31/501 , A61K31/5377 , A61K45/06 , C07D209/08 , C07D209/32 , C07D211/58 , C07D211/96 , C07D213/64 , C07D215/20 , C07D217/16 , C07D231/56 , C07D235/26 , C07D241/04 , C07D249/04 , C07D295/125 , C07D295/14 , C07D295/155 , C07D309/04 , C07D309/14 , C07D401/06 , C07D403/06 , C07D405/06 , C07D405/12 , C07D405/14 , C07D413/06 , C07D417/12 , C07D471/04 , C07D487/04
Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.
-
公开(公告)号：US20250152600A1
公开(公告)日：2025-05-15
申请号：US18742823
申请日：2024-06-13
Applicant: AbbVie Inc.
Inventor： Le Wang , John K. Pratt , Keith F. McDaniel , Steven D. Fidanze , Lisa Hasvold , James H. Holms , Warren M. Kati , Dachun Liu , Robert A. Mantei , William J. McClellan , George S. Sheppard , Carol K. Wada , Yujia Dai
IPC: A61K31/541 , A61K31/437 , A61K31/5025 , A61K31/5377 , A61K45/06 , C07D471/04 , C07D487/04
Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
-
公开(公告)号：US20180296566A1
公开(公告)日：2018-10-18
申请号：US16012379
申请日：2018-06-19
Applicant: AbbVie Inc.
Inventor： Le Wang , John K. Pratt , Keith F. McDaniel , Yujia Dai , Steven D. Fidanze , Lisa Hasvold , James H. Holms , Warren M. Kati , Dachun Liu , Robert A. Mantei , William J. McClellan , George S. Sheppard , Carol K. Wada
IPC: A61K31/541 , A61K45/06 , C07D487/04 , C07D471/04 , A61K31/5025 , A61K31/437 , A61K31/5377
Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
-
公开(公告)号：US20180193315A1
公开(公告)日：2018-07-12
申请号：US15907597
申请日：2018-02-28
Applicant: AbbVie Inc.
Inventor： Edward A. Kesicki , Arthur F. Kluge , Michael A. Patane , John H. Van Drie, JR. , Ce Wang , Maricel Torrent , Michael L. Curtin , Todd M. Hansen , Rick F. Clark , Robin R. Frey , Zhiqin Ji , Yujia Dai , William J. McClellan , Jane Gong , Gui-dong G. Zhu , Anthony Mastracchio , Michael R. Michaelides , Thomas D. Penning , Chunqiu C. Lai
IPC: A61K31/4184 , C07D403/06 , C07D498/10 , A61K31/4439 , A61K31/423 , C07D405/06 , C07D409/06 , C07D403/12 , C07D413/14 , C07D235/02 , C07D401/12 , C07D407/12 , C07D409/12 , C07D413/04 , C07D413/12 , C07D417/04 , C07D417/12 , C07D263/52 , C07D491/107 , C07D493/10 , C07D495/10 , C07D401/06
CPC classification number: A61K31/4184 , A61K31/423 , A61K31/4439 , C07D235/02 , C07D263/52 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/06 , C07D407/12 , C07D409/06 , C07D409/12 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/12 , C07D491/107 , C07D493/10 , C07D495/10 , C07D498/10
Abstract: Compounds having a structure of Formula (IX): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1-Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.
-
Patent Agency Ranking
公开(公告)号：US20160237084A1
公开(公告)日：2016-08-18
申请号：US15137502
申请日：2016-04-25
Applicant: AbbVie Inc.
Inventor： Le Wang , John Pratt , Lisa A. Hasvold , Dachun Liu , Yujia Dai , Steven D. Fidanze , James H. Holms , Robert A. Mantei , Keith F. McDaniel , George S. Sheppard , William J. McClellan
IPC: C07D471/04 , C07D519/00
CPC classification number: C07D471/04 , C07D519/00
Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, and R5 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
Abstract translation: 本发明提供式（I）化合物，其中R 1，R 2，R 3，R 4和R 5具有说明书中定义的任何值及其药学上可接受的盐，其可用作治疗疾病和病症的试剂 ，包括炎性疾病，癌症和艾滋病。 还提供了包含一种或多种式（I）化合物的药物组合物。
-
17.发明授权BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases 有权用于治疗癌症和免疫疾病的BCL-2选择性细胞凋亡诱导剂公开(公告)号：US09072748B2
公开(公告)日：2015-07-07
申请号：US14058164
申请日：2013-10-18
Applicant: AbbVie Inc.
Inventor： Milan Bruncko , Hong Ding , George A. Doherty , Steven W. Elmore , Lisa Hasvold , Laura A. Hexamer , Aaron R. Kunzer , Robert A. Mantei , William J. McClellan , Chang H. Park , Cheol-Min Park , Andrew M. Petros , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Gary T. Wang , Le Wang , Xilu Wang , Michael D. Wendt
IPC: C07D405/06 , C07D413/06 , C07D487/04 , C07D241/04 , C07D401/06 , A61K31/5377 , C07D209/32 , C07D211/96 , C07D213/64 , C07D215/20 , C07D217/16 , C07D231/56 , C07D235/26 , C07D249/04 , C07D295/125 , C07D295/14 , C07D309/14 , C07D401/12 , C07D405/12 , C07D405/14 , C07D417/12 , C07D471/04 , A61K31/407 , A61K31/495 , A61K31/496 , A61K31/501 , A61K45/06 , C07D403/06
CPC classification number: C07D401/12 , A61K31/407 , A61K31/495 , A61K31/496 , A61K31/501 , A61K31/5377 , A61K45/06 , C07D209/08 , C07D209/32 , C07D211/58 , C07D211/96 , C07D213/64 , C07D215/20 , C07D217/16 , C07D231/56 , C07D235/26 , C07D241/04 , C07D249/04 , C07D295/125 , C07D295/14 , C07D295/155 , C07D309/04 , C07D309/14 , C07D401/06 , C07D403/06 , C07D405/06 , C07D405/12 , C07D405/14 , C07D413/06 , C07D417/12 , C07D471/04 , C07D487/04
Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.
Abstract translation: 公开了抑制抗凋亡Bcl-2或Bcl-xL蛋白的活性的化合物，含有该化合物的组合物和治疗疾病的方法，其中表达抗凋亡Bcl-2蛋白。
-
公开(公告)号：US20210236508A1
公开(公告)日：2021-08-05
申请号：US16996090
申请日：2020-08-18
Applicant: AbbVie Inc.
Inventor： Le Wang , John K. Pratt , Keith F. McDaniel , Yujia Dai , Steven D. Fidanze , Lisa Hasvold , James H. Holms , Warren M. Kati , Dachun Liu , Robert A. Mantei , William J. McClellan , George S. Sheppard , Carol K. Wada
IPC: A61K31/541 , C07D487/04 , C07D471/04 , A61K31/437 , A61K31/5025 , A61K31/5377 , A61K45/06
Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
-
公开(公告)号：US20180071262A1
公开(公告)日：2018-03-15
申请号：US15727220
申请日：2017-10-06
Applicant: AbbVie Inc.
Inventor： Edward A. Kesicki , Arthur F. Kluge , Michael A. Patane , John H. Van Drie, JR. , Ce Wang , Maricel Torrent , Michael L. Curtin , Todd M. Hansen , Rick F. Clark , Robin R. Frey , Zhiqin Ji , Yujia Dai , William J. McClellan , Jane Gong , Gui-dong G. Zhu , Anthony Mastracchio , Michael R. Michaelides , Thomas D. Penning , Chunqiu C. Lai
IPC: A61K31/4184 , C07D498/10 , C07D403/06 , C07D493/10 , C07D491/107 , C07D263/52 , C07D417/12 , C07D417/04 , C07D413/12 , C07D413/04 , C07D409/12 , C07D407/12 , C07D401/12 , C07D235/02 , C07D413/14 , C07D403/12 , C07D409/06 , C07D405/06 , A61K31/423 , A61K31/4439 , C07D401/06 , C07D495/10
CPC classification number: A61K31/4184 , A61K31/423 , A61K31/4439 , C07D235/02 , C07D263/52 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/06 , C07D407/12 , C07D409/06 , C07D409/12 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/12 , C07D491/107 , C07D493/10 , C07D495/10 , C07D498/10
Abstract: Compounds having a structure of Formula (IX): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.
-
公开(公告)号：US20160143916A1
公开(公告)日：2016-05-26
申请号：US15008994
申请日：2016-01-28
Applicant: AbbVie Inc.
Inventor： Le Wang , John K. Pratt , Keith F. McDaniel , Yujia Dai , Steven D. Fidanze , Lisa Hasvold , James H. Holms , Warren M. Kati , Dachun Liu , Robert A. Mantei , William J. McClellan , George S. Sheppard , Carol K. Wada
IPC: A61K31/541 , A61K45/06 , A61K31/5025 , A61K31/437 , A61K31/5377
CPC classification number: A61K31/541 , A61K31/437 , A61K31/5025 , A61K31/5377 , A61K45/06 , C07D471/04 , C07D487/04
Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
Abstract translation: 本发明提供式（I）化合物，其中A1，A2，A3，A4，X1，X2，Y1，L1，G1，Rx和Ry具有说明书中定义的任何值及其药学上可接受的盐 ，其作为治疗疾病和病症（包括炎性疾病，癌症和AIDS）的药剂是有用的。 还提供了包含一种或多种式（I）化合物的药物组合物。
-
-
-
-
-
-
-
-
-
Search Results
24
records
(took 0.075 seconds)
